Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 08:30 ET | Source: AVITA Medical

Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment

AVITA Medical data at SRBC 2025 confirms RECELL® as standard of care, improving healing, reducing hospital stays, and lowering treatment costs
October 29, 2025 16:15 ET | Source: AVITA Medical

AVITA Medical to Announce Third Quarter 2025 Financial Results

AVITA Medical to announce Q3 2025 financial results on Nov 6; webcast to discuss performance and business highlights
October 28, 2025 16:30 ET | Source: AVITA Medical

AVITA Medical Welcomes Support for RECELL® in Burns in Australia

MSAC backs AVITA Medical’s RECELL® for burns, recognizing its safety, healing benefits, donor site sparing, and reduced hospital stays.
October 16, 2025 17:43 ET | Source: Bragar Eagel & Squire

AVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Avita allegedly revealed unpaid claim backlogs for Recell procedures, causing provider uncertainty and a 21% stock drop on August 8, 2025.
October 09, 2025 12:49 ET | Source: Bragar Eagel & Squire

AVITA REMINDER: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders

Avita revealed a six-month backlog of unpaid Recell claims due to CMS pricing delays, hurting demand and driving shares down 21% to $4.25 on August 8, 2025
October 03, 2025 07:45 ET | Source: Bragar Eagel & Squire

AVITA (RCEL) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into AVITA Medical, Inc. and Encourages Investors to Contact the Firm

Avita revealed CMS pricing delays caused a 6-month backlog in unpaid Recell claims, hurting demand; shares fell 21% to $4.25 on Aug 8, 2025.
September 25, 2025 17:24 ET | Source: Bragar Eagel & Squire

AVITA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

Avita revealed a six-month backlog of unpaid Recell claims, hurting demand. Shares fell $1.13, or 21%, from $5.38 on Aug 7 to $4.25 on Aug 8, 2025.
September 15, 2025 17:45 ET | Source: Bragar Eagel & Squire

AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

Avita stock dropped 21% after Q2 2025 results revealed CMS pricing delays caused a six-month backlog of unpaid Recell claims.
September 08, 2025 17:13 ET | Source: Bragar Eagel & Squire

AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

On Aug 7, 2025, Avita revealed a 6-month Recell claims backlog that hurt demand; shares fell 21% to $4.25.
September 04, 2025 08:25 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Avita, Coty, and Sensus and Encourages Investors to Contact the Firm

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AVITA Medical, Inc....